Core Insights - Personalis achieved significant milestones in 2025, including Medicare coverage for breast cancer and lung cancer surveillance, which enhances the legitimacy of its tests and allows for ongoing surveillance billing [1][7][5] - The company is targeting a clinical volume of 43,000 to 45,000 tests in 2026, representing approximately 170% year-over-year growth, with over 900 oncologists currently ordering the tests [2][8] - The NeXT Personal test demonstrates high sensitivity, capable of detecting one tumor DNA fragment in a million, which facilitates earlier detection of cancer recurrence compared to standard imaging [3][5] Clinical Performance - In Q4 2025, Personalis delivered 6,183 clinical tests, marking a 41% sequential increase and a 329% year-over-year increase, with over 16,000 tests delivered throughout the year [4][8] - The company is focused on scaling its ultra-sensitive NeXT Personal MRD assay, which is currently utilized by more than 900 oncologists [8][5] Financial Overview - For 2025, Personalis reported total revenue of $69.6 million, with Q4 revenue at $17.3 million, reflecting a strategic shift away from lower-value work [6][16] - The company anticipates 2026 revenue guidance of $78 million to $80 million, with a projected net loss of approximately $105 million and cash usage of about $100 million [6][24] Research and Development - Personalis is involved in over 35 studies to support the performance of NeXT Personal, with ongoing trials demonstrating its clinical utility in various cancer types [10][12] - Landmark studies, such as the TRACERx lung cancer study and the Royal Marsden breast cancer study, have shown strong sensitivity and specificity for NeXT Personal [10][11] Biopharma Collaboration - The company reported a nearly 240% growth in biopharma MRD revenue over 2024, indicating a stabilizing environment in the biopharma sector [14][15] - For 2026, biopharma revenue is expected to be between $55 million and $56 million, with MRD revenue projected at $20 million to $21 million [15][19] Market Strategy - Personalis plans to increase its dedicated field team to enhance market share, with an estimate of 20% of 2026 test volume expected from breast cancer and 15% to 20% from lung cancer [20][5] - The introduction of a new "Real-Time Variant Tracker" report aims to assist in detecting mutations during MRD surveillance, with positive early feedback from physicians [21][5]